Physician

Brian Nicholson Mathews, MD

According to 2025 Medicare claims, Brian Mathews, MD (NPI: 1841210713) practices hematology/oncology in the Huntsville, AL market, with the plurality of this provider's patient population coming from Madison, AL. This provider's primary affiliated billing organization is ONCOLOGY SPECIALTIES, P.C. (NPI: 1669425716; TIN: 630897317) and primary practice location at 35805-2606.

Mathews' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 992 traditional Medicare patients, billed 114,117 HCPCS/CPT codes, and received $2,517,128 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,015 prescription claims across 291 beneficiaries totaling $4,336,393 in drug costs, led by Xtandi (Enzalutamide). DME data shows 66 claims. Open Payments data shows 77 records totaling $2,165. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,555,736 and ending at $2,517,128. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,261,308 to $4,336,393. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,529 to $4,488.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,333	272,063	$2,555,736
2016	1,406	262,376	$3,077,207
2017	1,163	191,363	$2,406,103
2018	1,179	208,153	$3,159,267
2019	1,049	211,227	$3,170,631
2020	1,015	204,988	$2,815,031
2021	1,063	161,294	$2,651,105
2022	1,139	141,093	$2,240,170
2023	993	77,354	$1,544,110
2024	992	114,117	$2,517,128

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	351	2,654	$1,261,308
2016	376	2,816	$2,124,861
2017	365	3,128	$2,157,496
2018	358	3,022	$2,312,257
2019	332	2,798	$2,894,470
2020	293	2,287	$2,621,020
2021	305	2,189	$3,088,373
2022	327	2,173	$3,328,820
2023	286	2,067	$4,354,524
2024	291	2,015	$4,336,393

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	119	$33,553
2016	N/R	57	$15,786
2017	N/R	28	$1,653
2018	11	131	$10,629
2019	N/R	124	$4,454
2020	N/R	76	$4,405
2021	N/R	25	$1,438
2022	N/R	45	$7,066
2023	N/R	62	$6,642
2024	N/R	66	$2,835

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	390	875	$88
82728	Ferritin (blood protein) level	389	628	$13
80053	Blood test, comprehensive group of blood chemicals	733	1,541	$10
36415	Insertion of needle into vein for collection of blood sample	743	1,572	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	748	1,607	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	48	1,440	$663,574
Revlimid	Lenalidomide	38	1,001	$548,394
Kisqali	Ribociclib Succinate	17	476	$222,261
Lenalidomide	Lenalidomide	20	497	$221,222
Imbruvica	Ibrutinib	13	390	$213,589

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	18	$1,919
J8521	Capecitabine, oral, 500 mg	N	N/R	21	$521
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$207
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$188

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	77	$2,165	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Brian Nicholson Mathews, MD?

Tedicare shows public-source Medicare data for Brian Nicholson Mathews, MD (NPI 1841210713), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brian Nicholson Mathews, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Brian Nicholson Mathews, MD?

Brian Nicholson Mathews, MD is linked to ONCOLOGY SPECIALTIES, P.C. (billing NPI 1669425716) in the available physician profile data.

Does Brian Nicholson Mathews, MD have Open Payments data?

Brian Nicholson Mathews, MD has 77 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.